Related Experiment Video
Updated: Jun 2, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Metabolic Dysfunction-Associated Steatotic Liver Disease in Schizophrenia: A Systematic Review and Meta-analysis
Marcel Camino-I-Gibernau1, Diego A Gomez2, Ramiro Manzano-Nunez3
1Departamento de psiquiatría, PARC Sanitaria Sant Joan de deu, Barcelona, Spain.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 36% of individuals with schizophrenia, often overlooked. Key risk factors include metabolic syndrome, diabetes, and specific antipsychotics, highlighting a need for increased clinical awareness.
Area of Science:
- Hepatology
- Psychiatry
- Metabolic Disorders
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is the liver manifestation of metabolic syndrome.
- While cardiovascular risks in schizophrenia are known, hepatic steatosis is underrecognized.
- This study addresses the prevalence and risk factors of MASLD in schizophrenia patients.
Purpose of the Study:
- To estimate the pooled prevalence of MASLD in patients with schizophrenia.
- To identify risk factors associated with MASLD in this population.
- To raise awareness of the hepatic steatosis burden in schizophrenia.
Main Methods:
- Systematic review and meta-analysis of PubMed, Scopus, and Web of Science.
- Inclusion of observational studies on MASLD/NAFLD/MAFLD prevalence in adults with schizophrenia.
- Narrative synthesis of risk factors from multivariable analyses.
Main Results:
- Nine studies (28,702 patients) reported a pooled MASLD prevalence of 36% (95% CI: 28%-45%).
- Prevalence varied by diagnostic method (39% with imaging/biomarkers vs. 22% with administrative data).
- Independent risk factors included metabolic syndrome, type 2 diabetes, elevated BMI, dyslipidemia, antipsychotic polypharmacy, olanzapine, clozapine, quetiapine; risperidone showed a lower risk.
Conclusions:
- MASLD is prevalent (36%) in schizophrenia, with significant variation based on diagnostic modality.
- Identified risk factors underscore the need for greater clinical awareness and research.
- Current data highlight an overlooked clinical burden in schizophrenia patients.
More Related Videos
Related Concept Videos
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology
Hepatic Encephalopathy

